pyrazines has been researched along with Diabetic Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J | 1 |
| Anderwald, CH; Baumgartner-Parzer, S; Fürnsinn, C; Harreiter, J; Kosi-Trebotic, L; Krebs, M; Krssak, M; Luger, A; Smajis, S; Trattnig, S; Winhofer, Y; Wolf, P | 1 |
1 trial(s) available for pyrazines and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
Topics: Adipose Tissue; Aged; Austria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Down-Regulation; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Lipolysis; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Proton Magnetic Resonance Spectroscopy; Pyrazines; Risk Factors; Single-Blind Method; Stroke Volume; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left | 2016 |
1 other study(ies) available for pyrazines and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2013 |